InsiderSignal.AI

InsiderSignal.ai

KNSA - Kiniksa Pharmaceuticals International, Plc

Insider Sale by Patel Sanj K (COB, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Patel Sanj K, serving as COB, CEO at Kiniksa Pharmaceuticals International, Plc (KNSA), sold 508,339 shares at $51.96 per share, for a total transaction value of $26,415,228.00. Following this transaction, Patel Sanj K now holds 237,763 shares of KNSA.

This sale represents a 68.00% decrease in Patel Sanj K's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, April 28, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 30, 2026, 2 days after the trade was made.

Kiniksa Pharmaceuticals International, Plc operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Patel Sanj K

COB, CEO

Sanj K. Patel is the Chairman and Chief Executive Officer (CEO) of Kiniksa Pharmaceuticals International, Plc (KNSA), a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapies for patients with debilitating diseases and unmet medical needs.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel)[[3]](https://www.zoominfo.com/p/Sanj-Patel/894739082)[[5]](https://www.marketscreener.com/insider/SANJ-PATEL-A0NFO8/) He founded Kiniksa in 2015 and took the company public on NASDAQ in May 2018.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel)[[4]](https://boston.citybuzz.co/article/357084/syros-pharmaceuticals-appoints-sanj-k-patel-to-its-board-of-directors)[[5]](https://www.marketscreener.com/insider/SANJ-PATEL-A0NFO8/) Patel brings over 25 years of biopharmaceutical experience, including founding Synageva BioPharma in 2008, where he served as President and CEO, leading its $9.5 billion acquisition by Alexion Pharmaceuticals in 2015 after developing and gaining approval for Kanuma®, the first therapy for Lysosomal Acid Lipase Deficiency.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel)[[2]](https://ir.biocryst.com/news-releases/news-release-details/sanj-k-patel-appointed-biocrysts-board-directors)[[4]](https://boston.citybuzz.co/article/357084/syros-pharmaceuticals-appoints-sanj-k-patel-to-its-board-of-directors) Previously at Genzyme Corporation (1999-2008), he led U.S. sales, marketing, and commercial operations for key products like Myozyme®, Cerezyme®, Fabrazyme®, and Aldurazyme®, and directed clinical operations resulting in Fabrazyme®'s FDA approval in 2003.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel) Earlier roles were at Burroughs Wellcome, Hoechst Marion Roussel, and Fujisawa/Otsuka.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel) He holds a BSc with Honors in Biotechnology from the University of the South Bank, London, management studies from Ealing College, and pharmacology research from the Wellcome Foundation.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel)

View full insider profile →

Trade Price

$51.96

Quantity

508,339

Total Value

$26,415,228.00

Shares Owned

237,763

Trade Date

Tuesday, April 28, 2026

3 days ago

SEC Filing Date

Thursday, April 30, 2026

Filed 2 days after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning KNSA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6082757

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime